AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer

[1] Wu J(2016)Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy J Magn Reson Imaging 44 1107-15

[2] Gong G(2015)Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy Mol Cell 60 537-46

[3] Cui Y(2016)Triple-negative breast cancer: treatment challenges and solutions Breast Cancer (Dove Med Press) 8 93-107

[4] Li R(2012)Dissecting the heterogeneity of triple-negative breast cancer J Clin Oncol 30 1879-87

[5] Koren S(2016)Cancer statistics in China, 2015 CA Cancer J Clin 66 115-32

[6] Bentires-Alj M(2009)Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design Clin Breast Cancer 9 29-33

[7] Collignon J(2016)Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease Nat Rev Clin Oncol 13 674-690

[8] Lousberg L(2004)Facts and controversies in systemic treatment of metastatic breast cancer Oncologist 9 617-32

[9] Schroeder H(2004)A mystery of AHNAK/desmoyokin still goes on J Investig Dermatol 123 xiv-xv

[10] Jerusalem G(1989)A new high molecular mass protein showing unique localization in desmosomal plaque J Cell Biol 109 1511-8

[1] Wu J(2016)Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy J Magn Reson Imaging 44 1107-15

[2] Gong G(2015)Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy Mol Cell 60 537-46

[3] Cui Y(2016)Triple-negative breast cancer: treatment challenges and solutions Breast Cancer (Dove Med Press) 8 93-107

[4] Li R(2012)Dissecting the heterogeneity of triple-negative breast cancer J Clin Oncol 30 1879-87

[5] Koren S(2016)Cancer statistics in China, 2015 CA Cancer J Clin 66 115-32

[6] Bentires-Alj M(2009)Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design Clin Breast Cancer 9 29-33

[7] Collignon J(2016)Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease Nat Rev Clin Oncol 13 674-690

[8] Lousberg L(2004)Facts and controversies in systemic treatment of metastatic breast cancer Oncologist 9 617-32

[9] Schroeder H(2004)A mystery of AHNAK/desmoyokin still goes on J Investig Dermatol 123 xiv-xv

[10] Jerusalem G(1989)A new high molecular mass protein showing unique localization in desmosomal plaque J Cell Biol 109 1511-8